How to buy Mirum Pharmaceuticals stock (MIRM)

Mirum Pharmaceuticals is a biotechnology business based in the US. Mirum Pharmaceuticals shares (MIRM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $39.06 – a decrease of 1.56% over the previous week. Mirum Pharmaceuticals employs 294 staff and has a trailing 12-month revenue of around $264.4 million.

Our top picks for where to buy Mirum Pharmaceuticals stock

Buy Mirum Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Mirum Pharmaceuticals stock price (NASDAQ: MIRM)

Use our graph to track the performance of MIRM stocks over time.

Mirum Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$39.06
52-week range	$23.14 - $45.23
50-day moving average more info button	$40.35
200-day moving average more info button	$32.08
Wall St. target price	$61.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.37

Is it a good time to buy Mirum Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mirum Pharmaceuticals price performance over time

Historical closes compared with the close of $39.54 from 2024-10-28

1 week (2024-10-23)	2.92%
1 month (2024-09-30)	1.38%
3 months (2024-07-30)	-1.89%
6 months (2024-04-30)	57.47%

1 year (2023-10-30)	45.10%
2 years (2022-10-28)	65.93%
3 years (2021-10-29)	148.99%
5 years (2019-10-30)	432.88%

Mirum Pharmaceuticals financials

Revenue TTM	$264.4 million
Gross profit TTM	$64.7 million
Return on assets TTM	-12.27%
Return on equity TTM	-70.98%
Profit margin	-41.29%
Book value	$4.81
Market Capitalization more info button	$1.9 billion

TTM: trailing 12 months

Mirum Pharmaceuticals share dividends

We're not expecting Mirum Pharmaceuticals to pay a dividend over the next 12 months.

Mirum Pharmaceuticals share price volatility

Over the last 12 months, Mirum Pharmaceuticals's shares have ranged in value from as little as $23.14 up to $45.23. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirum Pharmaceuticals's is 1.137. This would suggest that Mirum Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Mirum Pharmaceuticals overview

Mirum Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. .

Frequently asked questions

What percentage of Mirum Pharmaceuticals is owned by insiders or institutions?
Currently 2.213% of Mirum Pharmaceuticals shares are held by insiders and 118.209% by institutions. How many people work for Mirum Pharmaceuticals?
Latest data suggests 294 work at Mirum Pharmaceuticals. When does the fiscal year end for Mirum Pharmaceuticals?
Mirum Pharmaceuticals's fiscal year ends in December. Where is Mirum Pharmaceuticals based?
Mirum Pharmaceuticals's address is: 950 Tower Lane, Foster City, CA, United States, 94404 What is Mirum Pharmaceuticals's ISIN number?
Mirum Pharmaceuticals's international securities identification number is: US6047491013 What is Mirum Pharmaceuticals's CUSIP number?
Mirum Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 604749101